$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022048113 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$42.27K	$312.9K	$25.66K
YoY Change	-57.3%	895.07%	-90.25%
Cost Of Revenue	$10.74K	$8.367K	$1.900K
YoY Change	2654.1%	1195.2%	52.0%
Gross Profit	$31.53K	$304.5K	$23.76K
YoY Change	-68.03%	888.77%	-90.93%
Gross Profit Margin	74.59%	97.33%	92.6%
Selling, General & Admin	$3.216M	$1.593M	$5.883M
YoY Change	78.11%	29.32%	322.23%
% of Gross Profit	10200.92%	523.11%	24760.44%
Research & Development	$305.5K	$532.8K	$359.4K
YoY Change	15.97%	48.46%	196.24%
% of Gross Profit	968.93%	174.97%	1512.63%
Depreciation & Amortization	$6.462K	$5.490K	$5.410K
YoY Change	125.94%	86.73%	84.64%
% of Gross Profit	20.5%	1.8%	22.77%
Operating Expenses	$3.747M	$2.351M	$6.242M
YoY Change	81.11%	13.79%	312.14%
Operating Profit	-$3.716M	-$2.047M	-$6.219M
YoY Change	88.57%	0.56%	396.41%
Interest Expense	$126.5K	$14.76K	$29.53K
YoY Change	-199.55%	-82.15%	-123.71%
% of Operating Profit
Other Income/Expense, Net	-$56.46K	$17.08K	$14.71K
YoY Change	-141.59%	-122.18%	-88.77%
Pretax Income	-$3.772M	-$2.030M	-$6.174M
YoY Change	92.28%	-3.92%	395.4%
Income Tax	$4.222K	-$82.45K	-$86.87K
% Of Pretax Income
Net Earnings	-$3.705M	-$1.859M	-$6.088M
YoY Change	105.09%	-5.71%	409.29%
Net Earnings / Revenue	-8764.97%	-594.19%	-23724.14%
Basic Earnings Per Share	-$0.11	-$0.06	-$0.20
Diluted Earnings Per Share	-$0.11	-$0.06	-$202.0K
COMMON SHARES
Basic Shares Outstanding	32.63M shares	31.31M shares	29.68M shares
Diluted Shares Outstanding	32.57M shares	31.31M shares	29.68M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.401M	$2.993M	$2.813M
YoY Change	-63.39%	223.66%	7.59%
Cash & Equivalents	$1.324M	$2.911M	$2.718M
Short-Term Investments	$77.58K	$82.76K	$95.55K
Other Short-Term Assets	$933.8K	$2.629M	$2.010M
YoY Change	-57.36%	69.62%	48.89%
Inventory	$20.49K	$21.86K	$22.70K
Prepaid Expenses
Receivables	$47.68K	$289.5K	$426.6K
Other Receivables	$500.0K	$3.713M	$2.715M
Total Short-Term Assets	$2.903M	$9.789M	$7.988M
YoY Change	-59.17%	169.85%	53.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$566.8K	$597.3K	$1.981M
YoY Change	-72.78%	-72.19%	-10.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$816.2K	$870.6K	$904.3K
YoY Change	-18.91%	-20.55%	-19.76%
Other Assets	$4.951M	$1.231M	$1.193M
YoY Change	129.71%	-40.64%	-39.55%
Total Long-Term Assets	$7.577M	$3.993M	$4.079M
YoY Change	44.5%	-24.9%	-23.34%
TOTAL ASSETS
Total Short-Term Assets	$2.903M	$9.789M	$7.988M
Total Long-Term Assets	$7.577M	$3.993M	$4.079M
Total Assets	$10.48M	$13.78M	$12.07M
YoY Change	-15.17%	54.08%	14.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.085K
YoY Change		-58.71%
Accrued Expenses	$1.201M	$1.247M	$1.597M
YoY Change	-18.59%	-43.39%	-35.29%
Deferred Revenue
YoY Change
Short-Term Debt	$1.866M	$1.574M	$1.610M
YoY Change	13.99%	-14.54%	-11.58%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.894M	$3.646M	$3.664M
YoY Change	13.24%	-16.69%	-21.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$893.1K	$956.3K	$1.042M
YoY Change	-26.92%	-27.36%	-25.31%
Total Long-Term Liabilities	$893.1K	$956.3K	$1.042M
YoY Change	-32.66%	-76.41%	-74.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.894M	$3.646M	$3.664M
Total Long-Term Liabilities	$893.1K	$956.3K	$1.042M
Total Liabilities	$4.787M	$4.602M	$4.640M
YoY Change	27.3%	-38.68%	-41.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$50.04M	-$46.34M
YoY Change
Common Stock	$32.63K	$32.31K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.100M	$9.100M
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.919M	$9.334M	$7.427M
YoY Change
Total Liabilities & Shareholders Equity	$10.48M	$13.78M	$12.07M
YoY Change	-15.17%	54.08%	14.64%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.705M	-$1.859M	-$6.088M
YoY Change	105.09%	-5.71%	409.29%
Depreciation, Depletion And Amortization	$6.462K	$5.490K	$5.410K
YoY Change	125.94%	86.73%	84.64%
Cash From Operating Activities	-$513.7K	-$3.429M	-$2.994M
YoY Change	-80.86%	137.49%	111.9%
INVESTING ACTIVITIES
Capital Expenditures	-$4.350K	-$22.03K	-$93.22K
YoY Change	-75.14%
Acquisitions
YoY Change
Other Investing Activities	-$1.519M	$0.00	$0.00
YoY Change	367.46%	-100.0%	-100.0%
Cash From Investing Activities	-$1.523M	-$22.03K	-$93.22K
YoY Change	344.83%	-84.27%	-66.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	603.5K	3.664M	0.000
YoY Change	-89.63%	-3232.64%	-100.0%
NET CHANGE
Cash From Operating Activities	-513.7K	-3.429M	-2.994M
Cash From Investing Activities	-1.523M	-22.03K	-93.22K
Cash From Financing Activities	603.5K	3.664M	0.000
Net Change In Cash	-1.433M	212.5K	-3.087M
YoY Change	-151.36%	-112.5%	86.8%
FREE CASH FLOW
Cash From Operating Activities	-$513.7K	-$3.429M	-$2.994M
Capital Expenditures	-$4.350K	-$22.03K	-$93.22K
Free Cash Flow	-$509.4K	-$3.407M	-$2.901M
YoY Change	-80.9%		105.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40700
	dei	Entity Registrant Name EntityRegistrantName	ABVC BioPharma, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0014658
	dei	Entity Address Address Line1 EntityAddressAddressLine1	44370 Old Warm Springs Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	668-0881
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ABVC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32632329	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2910613	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5828548	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	688633	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	736667	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	289474	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	280692	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	142225	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	145399	usd
CY2022Q2	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	3713319	usd
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1286618	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	21855	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	25975	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	82755	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	108147	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	981912	usd
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	110099	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	119309	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	39977	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	41157	usd
CY2022Q2	abvc	Prepayment For Longterm Investments PrepaymentForLongtermInvestments	639072	usd
CY2021Q4	abvc	Prepayment For Longterm Investments PrepaymentForLongtermInvestments	684720	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1301448	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	528354	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9789394	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	9625120	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	597318	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525881	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1294550	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1471899	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	870571	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	932755	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1080703	usd
CY2022Q2	us-gaap	Assets Assets	13782612	usd
CY2021Q4	us-gaap	Assets Assets	13698033	usd
CY2022Q2	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1574000	usd
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1640000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2085	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1246898	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1300803	usd
CY2022Q2	abvc	Advance From Customers AdvanceFromCustomers	10985	usd
CY2021Q4	abvc	Advance From Customers AdvanceFromCustomers	10985	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	350284	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347100	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	461612	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	393424	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3645864	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3692312	usd
CY2022Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	11980	usd
CY2021Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	10580	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	944266	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1124799	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4602110	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4827691	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32307329	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32307329	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28926322	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28926322	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	32307	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28926	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66240474	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58113667	usd
CY2022Q2	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1805920	usd
CY2021Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	2257400	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46335637	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38481200	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	303100	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	539660	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9334324	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8843653	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-153822	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	26689	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9180502	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13782612	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13698033	usd
CY2022Q2	us-gaap	Revenues Revenues	312860	usd
CY2021Q2	us-gaap	Revenues Revenues	31441	usd
	us-gaap	Revenues Revenues	338520	usd
	us-gaap	Revenues Revenues	294591	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	8367	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	646	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10263	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1891	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	304493	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	30795	usd
	us-gaap	Gross Profit GrossProfit	328257	usd
	us-gaap	Gross Profit GrossProfit	292700	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1592831	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1231692	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2783909	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2399287	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	532782	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	358878	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	892186	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	480193	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	225740	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	475740	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4917743	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	701480	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2351353	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2066310	usd
	us-gaap	Operating Expenses OperatingExpenses	8593838	usd
	us-gaap	Operating Expenses OperatingExpenses	3580960	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2046860	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2035515	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8265581	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3288260	usd
CY2022Q2	abvc	Interest Incomes InterestIncomes	39015	usd
CY2021Q2	abvc	Interest Incomes InterestIncomes	10722	usd
	abvc	Interest Incomes InterestIncomes	79190	usd
	abvc	Interest Incomes InterestIncomes	63251	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	14758	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	82671	usd
	us-gaap	Interest Expense InterestExpense	32971	usd
	us-gaap	Interest Expense InterestExpense	212900	usd
CY2022Q2	abvc	Rent Income RentIncome	32802	usd
CY2021Q2	abvc	Rent Income RentIncome	53331	usd
	abvc	Rent Income RentIncome	56926	usd
	abvc	Rent Income RentIncome	58198	usd
CY2021Q2	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties	800	usd
	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties	2400	usd
CY2022Q2	abvc	Gain Loss On Foreign Exchange Changes GainLossOnForeignExchangeChanges	10479	usd
CY2021Q2	abvc	Gain Loss On Foreign Exchange Changes GainLossOnForeignExchangeChanges	-5758	usd
	abvc	Gain Loss On Foreign Exchange Changes GainLossOnForeignExchangeChanges	18042	usd
	abvc	Gain Loss On Foreign Exchange Changes GainLossOnForeignExchangeChanges	-4807	usd
CY2021Q2	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-53591	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-101382	usd
CY2022Q2	us-gaap	Other Income OtherIncome	-50462	usd
CY2021Q2	us-gaap	Other Income OtherIncome	162	usd
	us-gaap	Other Income OtherIncome	-59872	usd
	us-gaap	Other Income OtherIncome	233	usd
	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	124400	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17076	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-77005	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61315	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70607	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2029784	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2112520	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8204266	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3358867	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-82451	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-59564	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-169318	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-110588	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1947333	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2052956	usd
	us-gaap	Profit Loss ProfitLoss	-8034948	usd
	us-gaap	Profit Loss ProfitLoss	-3248279	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-88336	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-81390	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-180511	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-148208	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1858997	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1971566	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7854437	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3100071	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-123221	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	364581	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-236560	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	400721	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1982218	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1606985	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8090997	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2699350	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31307329	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24421082	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29683402	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24420804	shares
	us-gaap	Profit Loss ProfitLoss	-8034948	usd
	us-gaap	Profit Loss ProfitLoss	-3248279	usd
	us-gaap	Depreciation Depreciation	10902	usd
	us-gaap	Depreciation Depreciation	5869	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4917743	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	701480	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-101382	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	124400	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18831	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-170118	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-111388	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8782	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	137312	usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	784714	usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	219020	usd
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	2435935	usd
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	12346	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2473	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2085	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-17997	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-21915	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	201591	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1085	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	80760	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	4427	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6423618	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2857078	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	115246	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	421974	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-115246	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-421974	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3663925	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	306836	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	236498	usd
	abvc	Repayment Of Long Term Bank Loans RepaymentOfLongTermBankLoans	4396	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3663925	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-74734	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-91030	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9419	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2965969	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3344367	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5001371	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3599246	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1657004	usd
	us-gaap	Interest Paid Net InterestPaidNet	24348	usd
	us-gaap	Interest Paid Net InterestPaidNet	69623	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2662067	usd
CY2021Q1	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-1195323	usd
CY2021Q1	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	36140	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1728624	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	250000	usd
CY2021Q2	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2052956	usd
CY2021Q2	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	364581	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	515989	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4466263	usd
CY2022Q1	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-6087615	usd
CY2022Q1	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-113339	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7361391	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3663925	usd
CY2022Q2	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	225740	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1947333	usd
CY2022Q2	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-123221	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9180502	usd
CY2016Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.
CY2017Q3	abvc	Percentage Of Common Shares Issued And Outstanding PercentageOfCommonSharesIssuedAndOutstanding	0.73	pure
	us-gaap	Fiscal Period FiscalPeriod	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fiscal Year</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	360000000	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2910613	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5828548	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	688633	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	736667	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2021Q2	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	6	usd
CY2021Q2	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	475740	usd
	abvc	Labour Pension Fund Percentage LabourPensionFundPercentage	0.06	pure
	abvc	Percentage Of Monthly Contributions PercentageOfMonthlyContributions	0.06	pure
CY2022Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3309	usd
CY2021Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2859	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	6646	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	5362	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2022Q2	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	225740	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	66706	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	84620	usd
CY2022Q2	abvc	Allowance For Inventory Valuation And Obsolescence Loss AllowanceForInventoryValuationAndObsolescenceLoss	-145012	usd
CY2021Q4	abvc	Allowance For Inventory Valuation And Obsolescence Loss AllowanceForInventoryValuationAndObsolescenceLoss	-155370	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	21855	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	25975	usd
	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	4917743	usd
	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	701480	usd
	abvc	Beneficial Conversion Feature BeneficialConversionFeature	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
CY2018Q4	abvc	Co Dev Agreement Description CoDevAgreementDescription	the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	100161	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	96725	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3899531	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3840352	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3302213	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3314471	usd
CY2022Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	597318	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525881	usd
CY2022Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	5491	usd
CY2021Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2941	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	10902	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	5869	usd
	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Genepharm Biotech Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	870571	usd
CY2021Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	932755	usd
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	870571	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	932755	usd
	abvc	Purchase Additional Shares PurchaseAdditionalShares	317000	shares
CY2022Q2	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	639072	usd
CY2021Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	684720	usd
	abvc	Share Of Equity Method Investee Losses ShareOfEquityMethodInvesteeLosses	-101382	usd
CY2018Q2	us-gaap	Stock Issued1 StockIssued1	5000000	usd
CY2018Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2
CY2018Q2	abvc	Shares Offering Price Percentage SharesOfferingPricePercentage	0.80	pure
CY2018Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	500000	usd
CY2020Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.20	pure
CY2020Q2	abvc	Aggregate Principal And Accrued Interest Expense AggregatePrincipalAndAccruedInterestExpense	354722	usd
CY2020Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	192784	shares
CY2018Q2	us-gaap	Stock Issued1 StockIssued1	5000000	usd
CY2018Q3	us-gaap	Stock Issued1 StockIssued1	5000000	usd
CY2019Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.70	pure
CY2019Q3	abvc	Public Equity Offering Exceed Amount PublicEquityOfferingExceedAmount	10000000	usd
CY2020	abvc	Shares Issued1 SharesIssued1	111112	shares
CY2019Q3	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have been issued during the year ended December 31, 2020On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the “C.L.L. Note”) in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the “C.L.L.”), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $.50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of common stock. These common shares have been issued during the year ended December 31, 2020
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.25
CY2021Q3	abvc	Convertible Promissory Note ConvertiblePromissoryNote	2500000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1111112	shares
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1574000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1640000	usd
CY2020Q3	abvc	Principal Amount principalAmount	7500000	twd
CY2020Q3	abvc	Principal Amount principalAmount	252000	usd
CY2017Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-01-19
CY2022Q1	abvc	Principal Amount principalAmount	20000000	twd
CY2022Q1	abvc	Principal Amount principalAmount	672000	usd
CY2022Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P6Y
CY2019Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000000	usd
CY2020Q4	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2021Q4	abvc	Principal Amount principalAmount	650000	twd
CY2020Q2	abvc	Loan From Paycheck Protection Program LoanFromPaycheckProtectionProgram	124400	usd
CY2020Q2	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	abvc	Loan From Paycheck Protection Program LoanFromPaycheckProtectionProgram	132331	usd
CY2021Q1	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	abvc	Promissory Note Description PromissoryNoteDescription	The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.
CY2021Q1	abvc	Loan From Paycheck Protection Programs LoanFromPaycheckProtectionPrograms	104167	usd
CY2021Q1	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01	pure
CY2019Q1	abvc	Unsecured Loan Agreements Description UnsecuredLoanAgreementsDescription	In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose.
CY2022Q2	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2021Q2	us-gaap	Interest Expense Other InterestExpenseOther	3222	usd
	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
	us-gaap	Interest Expense Other InterestExpenseOther	6426	usd
CY2020Q1	us-gaap	Unsecured Debt UnsecuredDebt	100000	usd
CY2020Q3	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.015	pure
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	142225	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	145399	usd
CY2022Q2	abvc	Due Fromthe Related Parties Current DueFromtheRelatedPartiesCurrent	3713319	usd
CY2021Q4	abvc	Due Fromthe Related Parties Current DueFromtheRelatedPartiesCurrent	1286618	usd
CY2022Q2	abvc	Advanced An Aggregate Amount AdvancedAnAggregateAmount	547525	usd
CY2021Q4	abvc	Advanced An Aggregate Amount AdvancedAnAggregateAmount	49110	usd
	us-gaap	Assets Average Outstanding AssetsAverageOutstanding	531384	usd
CY2021	us-gaap	Assets Average Outstanding AssetsAverageOutstanding	33520	usd
CY2022Q2	us-gaap	Longterm Construction Loan Current And Noncurrent LongtermConstructionLoanCurrentAndNoncurrent	500000	usd
CY2022Q2	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	1000000	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1
	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.20	pure
CY2022Q2	us-gaap	Due From Affiliate Noncurrent DueFromAffiliateNoncurrent	1559	usd
CY2021Q4	us-gaap	Due From Affiliate Noncurrent DueFromAffiliateNoncurrent	1889	usd
	abvc	Loan Agreement Total Amount LoanAgreementTotalAmount	1348000	usd
CY2022Q2	abvc	Interest Rate InterestRate	0.065	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-11-30
CY2022Q1	abvc	Loan Agreement Total Amount LoanAgreementTotalAmount	507000	usd
CY2022Q1	abvc	Interest Rate InterestRate	0.065	pure
CY2022Q2	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	116640	usd
CY2021Q4	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	124972	usd
	abvc	Schedule Of Related Party Transactions Amount Due To Related Party ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst (Australia)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132,443</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>AsiaGene</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,017</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>YuanGene</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,205</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The Jiangs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">156,576</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,131</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">461,612</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	461612	usd
CY2021Q4	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	393424	usd
CY2022Q2	abvc	Accrued Interest AccruedInterest	40878	usd
CY2021Q4	abvc	Accrued Interest AccruedInterest	40878	usd
CY2018	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	The advances bear interest rate of 12% per annum.
CY2022Q2	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	156576	usd
CY2021Q4	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	168131	usd
CY2022Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5401	usd
CY2021Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5694	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	10714	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	10992	usd
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	abvc	Common Stock Share Authorized CommonStockShareAuthorized	360000000	shares
CY2016Q2	abvc	Agreement Description AgreementDescription	the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.
CY2016Q3	abvc	Agreement Description AgreementDescription	the Company issued 1,468,750 shares (“Shares”) of the Company’s Common Stock, par value $0.001 (the “Offering”) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.
CY2017Q1	abvc	Agreement Description AgreementDescription	the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2000000	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4220000	usd
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	556075	usd
	abvc	Warrants Term WarrantsTerm	P5Y
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2000000	shares
CY2019Q2	abvc	Financial Amendment Description FinancialAmendmentDescription	the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock.
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	644972	shares
	us-gaap	Professional Fees ProfessionalFees	4514800	usd
CY2022Q2	abvc	Stock Subscription Receivable StockSubscriptionReceivable	1805920	usd
CY2021Q4	abvc	Stock Subscription Receivable StockSubscriptionReceivable	2257400	usd
CY2019Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4872340	usd
CY2019Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7
CY2019Q3	abvc	Debt Conversion Converted Instrument Amount DebtConversionConvertedInstrumentAmount	4872340	usd
CY2019Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	696051	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50000	shares
CY2021Q2	us-gaap	Share Price SharePrice	5
CY2020Q4	abvc	Warrant Issued WarrantIssued	200000	shares
CY2020Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	2.25
CY2020Q4	abvc	Warrant Term WarrantTerm	P5Y
CY2020Q4	abvc	Issuance Of Common Stock IssuanceOfCommonStock	3384615	shares
CY2020	abvc	Aggregate Common Stock Shares AggregateCommonStockShares	915856	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1111112	shares
CY2021Q3	abvc	Convertible Promissory Note Value ConvertiblePromissoryNoteValue	2500000	usd
CY2021Q3	abvc	Description Of Public Offering DescriptionOfPublicOffering	the Company closed its public offering (the “Public Offering”) of 1,100,000 units (the “Units”), with each Unit consisting of one share of the Company’s common stock, one Series A warrant (the “Series A Warrants”) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Public Warrants”) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021 (as amended, the “Original Registration Statement”), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the “S-1MEF,” together with the Original Registration Statement, the “Registration Statement”). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.
CY2021Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4244452	usd
CY2021Q4	abvc	Aggregate Common Stock Shares AggregateCommonStockShares	673605	shares
CY2021Q4	abvc	Consulting Agreement Desciption ConsultingAgreementDesciption	In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021. In January 2022, the Company agreed to pay the deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued at $3.29 per share on the grant date. These shares have been issued in January 2022.
CY2022Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	75000	shares
CY2022Q1	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	169500	usd
CY2022Q1	us-gaap	Share Price SharePrice	2.26
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.45
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	545182	shares
CY2020Q4	abvc	Conversion Price ConversionPrice	2
CY2020Q4	abvc	Consulting Fees ConsultingFees	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1280002	shares
CY2021Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0851	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.09
CY2021Q2	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
CY2022Q2	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants	$0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	761920	shares
CY2022Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1858997	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1971566	usd
CY2022Q2	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	31307329
CY2021Q2	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	24421082
CY2022Q2	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	31307329
CY2021Q2	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	24421082
CY2022Q2	abvc	Basic Loss Per Share BasicLossPerShare	-0.06
CY2021Q2	abvc	Basic Loss Per Share BasicLossPerShare	-0.08
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7854437	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3100071	usd
	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	29683402
	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	24420804
	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	29683402
	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	24420804
	abvc	Basic Loss Per Share BasicLossPerShare	-0.26
	abvc	Basic Loss Per Share BasicLossPerShare	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1294550	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1471899	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	350284	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	347100	usd
CY2022Q2	abvc	Operating Lease Liabilitienoncurrent OperatingLeaseLiabilitienoncurrent	944266	usd
CY2021Q4	abvc	Operating Lease Liabilitienoncurrent OperatingLeaseLiabilitienoncurrent	1124799	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	88270	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	86280	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	174127	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	165127	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	174127	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	165127	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M29D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0137	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0139	pure
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29683402	shares
CY2022Q2	abvc	Present Value Of Future Minimum Lease Payment Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions	1294550	usd
CY2022Q2	abvc	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	176945	usd
CY2022Q2	abvc	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	358824	usd
CY2022Q2	abvc	Operating Leases Future Minimum Payment Due In Three Years OperatingLeasesFutureMinimumPaymentDueInThreeYears	373899	usd
CY2022Q2	abvc	Operating Leases Future Minimum Payment Due In Four Years OperatingLeasesFutureMinimumPaymentDueInFourYears	338676	usd
CY2022Q2	abvc	Operating Leases Future Minimum Payment Due Thereafter OperatingLeasesFutureMinimumPaymentDueThereafter	56916	usd
CY2022Q2	abvc	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	1305260	usd
CY2022Q2	abvc	Interest Portion Of Minimum Lease Payments Sale Leaseback Transaction InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction	10710	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	531147	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	188550	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	56075	usd
CY2019Q1	abvc	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets	485684	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	10440	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	1271896	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	56204	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	251335	usd
CY2019Q1	abvc	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability	-267256	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	2880	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	577675	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	694221	usd
CY2019Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	43647626	usd
CY2019Q1	abvc	Percentage Of Goodwill PercentageOfGoodwill	1	pure
CY2019Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43647626	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2022Q2	us-gaap	Goodwill Goodwill		usd
CY2022Q2	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment		usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
	abvc	Repayment Of Long Term Bank Loans RepaymentOfLongTermBankLoans		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	abvc	Share Of Equity Method Investee Losses ShareOfEquityMethodInvesteeLosses		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	1.13	pure
CY2022Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2021Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001173313
CY2022Q2	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties		usd
CY2022Q2	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd

Files In Submission

Name	View Source	Status
0001213900-22-048113-index-headers.html	Edgar Link	pending
0001213900-22-048113-index.html	Edgar Link	pending
0001213900-22-048113.txt	Edgar Link	pending
0001213900-22-048113-xbrl.zip	Edgar Link	pending
abvc-20220630.xsd	Edgar Link	pending
f10q0622ex31-1_abvcbio.htm	Edgar Link	pending
f10q0622ex31-2_abvcbio.htm	Edgar Link	pending
f10q0622ex32-1_abvcbio.htm	Edgar Link	pending
f10q0622ex32-2_abvcbio.htm	Edgar Link	pending
f10q0622_abvcbio.htm	Edgar Link	pending
abvc-20220630_cal.xml	Edgar Link	unprocessable
abvc-20220630_def.xml	Edgar Link	unprocessable
abvc-20220630_lab.xml	Edgar Link	unprocessable
abvc-20220630_pre.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
f10q0622_abvcbio_htm.xml	Edgar Link	completed
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2022 Q3 Form 10-Q Financial Statement

#000121390022048113 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2022 Q3 Form 10-Q Financial Statement

#000121390022048113 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc